Exceptional Revenue Growth
Revenue grew 33.9% YoY to $761.7M in Q1 FY2026 from $569.0M in Q1 FY2025, reflecting strong demand for PODD's insulin delivery products and continued market penetration.
Source: 10-Q Income Statement
Computed from published fixed rules, not a model's judgement — though one input, the count of high-severity risks, comes from the AI analysis below.
Not investment advice and not a price target: it scores the quarter's fundamentals, not the stock. Full methodology →
AI Takeaway
PODD delivered a strong Q1 FY2026 with revenue surging 33.9% YoY to $761.7M and net income more than doubling to $91.1M, while the company returned $300M to shareholders via buybacks.
Revenue
$761.7M
+33.87% YoY
EPS (Diluted)
$1.30
+160.00% YoY
Gross Margin
69.5%
-2.4 pts YoY
Operating Income
$122.1M
+37.50% YoY
Source: SEC XBRL
Insulet (PODD) reported Q1 FY2026 revenue of $761.7M, up 33.9% year over year. Operating margin was 16.0%, up 0.4 points from 15.6% a year earlier. Operating cash flow was $113.8M, up 78.4% year over year. PODD's fiscal Q1 FY2026 corresponds to calendar Q1 2026.
Last 4 quarters: 4 beats
| Quarter | Actual EPS (USD) | Consensus (USD) | Result |
|---|---|---|---|
| Jun 2026 | 1.66 | 1.48 | Beat +12.2% |
| Mar 2026This filing | 1.42 | 1.22 | Beat +16.2% |
| Dec 2025 | 1.55 | 1.48 | Beat +4.5% |
| Sep 2025 | 1.24 | 1.16 | Beat +6.5% |
Adjusted (non-GAAP) EPS of $1.42 versus the $1.22 analyst consensus — a +16.2% beat for Mar 2026. Analyst consensus is quoted on the adjusted (non-GAAP) basis the street uses. GAAP diluted EPS for this quarter was $1.30.
Compiled by AI from this SEC filing
Revenue grew 33.9% YoY to $761.7M in Q1 FY2026 from $569.0M in Q1 FY2025, reflecting strong demand for PODD's insulin delivery products and continued market penetration.
Source: 10-Q Income Statement
Net income jumped 157.3% YoY to $91.1M from $35.4M, with EPS (diluted) rising to $1.30 from $0.50, indicating significant operating leverage as revenue growth outpaced expense growth.
Source: 10-Q Income Statement
R&D expenses increased 50.5% YoY to $89.7M, outpacing revenue growth, signaling continued heavy investment in product innovation and pipeline development to sustain long-term competitive positioning.
Source: 10-Q Income Statement
Operating cash flow nearly doubled, rising 78.4% YoY to $113.8M from $63.8M, demonstrating improved cash conversion and underlying business quality.
Source: 10-Q Cash Flow Statement
PODD executed $300M in share repurchases in Q1 FY2026 (vs. $0 in Q1 FY2025), driving financing cash outflow of -$319.9M and reflecting management's confidence in the company's intrinsic value.
Source: 10-Q Cash Flow Statement
Compiled by AI from this SEC filing · 0 high, 5 medium, 0 low
Gross margin declined 240 basis points YoY to 69.5% from 71.9%, as cost of revenue grew 45.5%—significantly faster than revenue growth of 33.9%. Sustained cost pressure could erode profitability if not offset by pricing power or operational efficiencies.
Source: 10-Q Income Statement & Key Ratios
SG&A expenses reached $317.2M in Q1 FY2026, representing approximately 41.6% of revenue. While the ratio improved slightly YoY, the absolute dollar increase of $56.5M (+21.7%) highlights ongoing cost intensity in sales and marketing as the company expands its commercial footprint.
Source: 10-Q Income Statement
Current liabilities increased 32.1% YoY to $687.5M while current assets fell 26.6% to $1,709.5M. Although the current ratio remains healthy at 2.49, the directional trend warrants monitoring as the company deployed significant cash on buybacks.
Source: 10-Q Balance Sheet
Total assets fell 15.1% YoY to $2,987.2M, largely driven by a $618.9M reduction in current assets, partly attributable to the $300M share repurchase program. This reduces the company's financial buffer for future investments or downturns.
Source: 10-Q Balance Sheet
The debt-to-equity ratio stands at 1.29, indicating meaningful financial leverage. With stockholders' equity declining 2.1% YoY to $1,302.6M and total liabilities at $1,684.6M, the balance sheet carries moderate leverage that could constrain flexibility in a rising interest rate environment.
Source: 10-Q Balance Sheet & Key Ratios
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue $M | 761.70 $M | 569.00 $M | +33.87% |
Cost of Revenue $M | 232.70 $M | 159.90 $M | +45.53% |
Gross Profit $M | 529.10 $M | 409.00 $M | +29.36% |
Operating Income $M | 122.10 $M | 88.80 $M | +37.50% |
Net Income $M | 91.10 $M | 35.40 $M | +157.34% |
EPS (Basic) $ | 1.30 $ | 0.50 $ | +160.00% |
EPS (Diluted) $ | 1.30 $ | 0.50 $ | +160.00% |
R&D Expense $M | 89.70 $M | 59.60 $M | +50.50% |
SG&A Expense $M | 317.20 $M | 260.70 $M | +21.67% |
Answers draw on this SEC filing and the data on this page
Insulet delivered strong revenue growth and a net income surge in Q2 FY2026, driven by Omnipod 5 demand, though rising costs and product correction charges pressured margins.
Insulet Corporation (PODD) delivered strong FY2025 revenue growth of 30.7% to $2.71B, with operating income surging 53.4%, though net income fell 40.9% to $247.1M due to non-operating charges, while operating cash flow reached a record $569.3M.
Other companies in Health Care Equipment